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Improvement in tubercular cavities 
following adjuvant treatment with 
endobronchial valves: a case report
In 2010, multidrug-resistant tuberculosis (MDR-TB) 
occurred in 650 000 of the 12 million TB cases world-
wide,1 with extensively drug-resistant (XDR) TB com-
prising 9% of the MDR-TB cases.2 Treatment success 
is between 44% and 60%.3 We hypothesised that a 
recent form of lung collapse therapy—the insertion 
of Zephyr® endobronchial valves (EBVs; Pulmonx, 
Redwood, CA, USA)—may be effective in the treat-
ment of MDR/XDR-TB. This minimally invasive pro-
cedure is usually indicated for reducing emphysema-
associated hyperinfl ation.4 The one-way valve allows 
air and secretions to leave the lobe, but prevents air 
from entering, bringing about lobar collapse.
A 29-year-old female patient was admitted for 
treatment for XDR-TB in January 2011. She had 
been diagnosed with MDR-TB in Romania in 2006, 
with a further relapse in 2009. In 2011, the diagnosis 
was changed to XDR-TB. She was considered ineli-
gible for surgery due to extensive disease.
Sputum culture recorded heavy growth of Myco-
bacterium tuberculosis. A computed tomography (CT) 
scan (26 January 2011) showed multiple cavities in 
the left lower lobe, left upper lobe (LUL), right mid-
dle lobe (RML), and right lower lobe. 
Based on the results of drug susceptibility testing, 
treatment was initiated in January 2011 with intra-
venous imipenem/cilastatin, amikacin, linezolid and 
oral clofazimine. The patient showed no improvement 
in asthenia, persistent coughing, intermittent fever or 
haemoptysis. Continuous evaluation by sputum anal-
ysis and CT (March 2011) showed no improvement.
Given the patient’s deteriorating condition, we 
considered EBV placement. Pre-treatment CT was 
performed (Figure 1A). On 19 May 2011, two 4-mm 
Zephyr® valves were inserted into the lateral and 
medial segmental bronchi of the middle lobe bron-
chus under local anaesthesia and conscious seda-
tion. On 27 May 2011, terizidone was added to the 
treatment.
A follow-up CT at 1 month (Figure 1B) showed 
a marked reduction in the size of the RML cavity. 
However, sputum culture remained positive. The fi rst 
negative culture was obtained in a sample on 21 Sep-
tember. Treatment with TMC207 (an experimental 
drug) was commenced on 1 October. In October, the 
direct sample was sporadically positive. At the end of 
October, both sputum smear and culture became de-
fi nitively negative. A CT scan in November 2011 (not 
provided) showed resolution of the RML cavity. 
On 11 January 2012, in a single procedure, the two 
EBVs were removed from the RML, and a 5.5-mm 
Zephyr® valve was placed in the apicoposterior branch 
of the LUL where a cavity persisted (Figure 2A). 
Follow-up CT at 1 month showed that the cavity in 
the LUL had reduced in size (Figure 2B). The patient 
was now asymptomatic.
A recently conducted 10-month follow-up CT (Oc-
tober 2012) demonstrated a further reduction in the 
size of the LUL cavity (Figure 2C) and stability of 
the RML (Figure 1C). Sputum smear and culture 
r emained negative. The remaining EBV was subse-
quently removed.
We hypothesised that using Zephyr® EBV to cre-
ate hypoventilation and hypo-oxygenation of the 
lung lobe would promote healing of the tubercular 
cavity. In our case, Zephyr® EBV placement resulted 
in reductions in cavity size in each of the treated lobes 
within 1 month. Sputum smear and culture became 
negative 5 months after EBV placement. No EBV-
r elated complications occurred. 
To our knowledge, our case provides the only 
Figure 1 Chest CTs clearly showing changes in the cavity in the RML. A. Pre-treatment CT scan (May 2011) clearly showing the 
cavity (2.0 × 1.1 cm) in the RML (arrow). B. 1-month follow-up CT scan (June 2011) showing resolution of the cavity (arrow) and 
the two EBVs in place (arrowheads). Of note, there was a spontaneous reduction in the size of a cavity in the LUL (from 3.2 × 1.9 to 
2.1 × 1.5 cm), which was later targeted (see Figure 2). C. 17-month follow-up CT scan (October 2012) demonstrating stability of 
the RML after removal of the EBVs. CT = computed tomography; RML = right middle lobe; EBV = endobronchial valve.
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radio graphic evidence supporting the effectiveness of 
EBVs in closing tubercular cavities. The only other 
reports on a similar technique are from Russia,5 
where improvement in the tubercular process was re-
ported in 89 patients with MDR-TB and 118 patients 
with infi ltrative pulmonary TB.
More detailed information on this case (clinical 
outcomes and high-resolution fi gures) can be obtained 
from the corresponding author upon request.
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Figure 2 Chest CTs clearly showing changes in the cavity in the LUL. A. CT scan 2 months before second EBV implantation 
(November 2011). The size of the cavity in the LUL had remained stable (2.1 × 1.2 cm) since the CT scan taken in June 2011 (see 
Figure 1B). B. 1-month follow-up CT scan (February 2012) showing a reduction in the size of the cavity (1.7 × 1.0 cm) in the LUL 
(arrow). C. 10-month follow-up CT scan (October 2012) showing resolution of the cavity (EBVs still in place). CT = computed 
t omography; LUL = left upper lobe; EBV = endobronchial valve.
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